The influence of common, CNS-acting, drug prescriptions on outcomes from an intensive upper-limb rehabilitation program

Ainslie Johnstone [1], Fran Brander [2,3], Kate Kelly [2,3], Sven Bestmann [1,4], Nick Ward [1,2,3]

Affiliations

1. Department for Clinical and Movement Neuroscience, UCL Queen Square Institute of Neurology, University College London, London, UK
2. The National Hospital for Neurology and Neurosurgery, London, UK
3. UCLP Centre for Neurorehabilitation, London, UK
4. Wellcome Centre for Human Neuroimaging, UCL Queen Square Institute of Neurology, University College London, London, UK

Keywords: upper-limb impairment, motor function, rehabilitation, drugs, antidepressant, GABA agonist, antiepileptic

Word Count: main text ~3881 words + 277 word abstract

Tables and Figures

Table 1: Admission information for included and excluded participants

Figure 1: The effect of GABA agonist prescription on measures of upper-limb function, across time.

Figure 2: SCA of the effect of GABA agonist prescription on measures of upper-limb function at admission (A) or improvement (B).

Figure 3: The effect of antiepileptic prescription on measures of upper-limb function, across time.

Figure 4: SCA of the effect of antiepileptic prescription on measures of upper-limb function at admission (A) or improvement (B).

Figure 5: SCA of the effect of antidepressant prescription on measures of upper-limb function at admission (A) or improvement (B).

Figure 6: HADS score and upper-limb function scores split by antidepressant prescription

Figure 7: SCA of the effect of HADS score on measures of upper-limb function at admission (A) or improvement (B).

Abstract

Difficulty using the upper-limb is a major barrier to independence for many patients post-stroke or brain injury. High dose rehabilitation can result in clinically significant improvements in function even years after the incident, however there is still high variability in patient responsiveness to such interventions that cannot be explained by age, sex or time since stroke.

This retrospective study investigated whether prescription of certain CNS-acting drug classes- GABA agonists, antiepileptics and antidepressants- influenced outcomes on the 3 week intensive Queen Square Upper-Limb (QSUL) programme.

For 277 stroke or brain injury patients upper-limb impairment and activity was assessed at admission to the programme and at 6 months post-discharge, using the upper limb component of the Fugl-Meyer (FM), Action Research Arm Test (ARAT), and Chedoke Arm and Hand Activity Inventory (CAHAI). Drug prescriptions were obtained from primary care physicians at referral. Specification curve analysis (SCA) was used to protect against selective reporting results and add robustness to the conclusions of this retrospective study.

GABA agonist prescription had a significant negative effect on upper-limb scores at admission but did not impact programme-induced improvements. There were no effects of antiepileptic drug prescriptions on either admission scores, or improvement during the programme. Antidepressant prescriptions did not impact admission scores but resulted in reduced improvement in upper-limb function, even when accounting for anxiety and depression scores.

These results demonstrate that, when prescribed appropriately, GABA agonists do not impair patient's ability to benefit from rehabilitation programmes. Patients prescribed antidepressants, however, performed poorer than expected on the QSUL rehabilitation programme. While the reasons for this effect are unclear, identifying these patients prior to admission may allow for better accommodation of differences in their rehabilitation needs.

Introduction

Stroke is the most common cause of long-term neurological disability worldwide (Feigin et al. 2014). Currently, half of all people who survive a stroke are left disabled, with a third relying on others to assist with activities of daily living (Association 2016). A major contributor to ongoing physical disability is persistent difficulty in using the upper-limb (Broeks et al., 1999). For many years it was believed that spontaneous upper-limb recovery occurred in the first 3 months following a stroke, with only small rehabilitation-induced improvements happening after this period (Krakauer et al. 2012). However, recent studies have demonstrated that with specific, high-dose training chronic patients can experience clinically significant improvements in upper-limb function (Mawase et al. 2020; Allman et al. 2016; Ward, Brander, and Kelly 2019). Yet despite these positive results, there is a degree of variability in patient outcomes that cannot be explained by impairment at admission or other patient characteristics (Ward, Brander, and Kelly 2019). Identifying factors influencing this variability is therefore of high priority if similar high-intensity interventions are to be effectively developed.

There is an increasing wealth of literature, in both animals and humans, indicating that certain commonly used prescription drugs influence motor recovery following a brain lesion. Experimental findings from humans (Dam et al. 1996; Pariente et al. 2001; Acler et al. 2009; Zittel, Weiller, and Liepert 2008; Chollet et al. 2011) indicate that selective serotonin reuptake inhibitors (SSRIs) may boost practice-dependent motor improvements, while animal experiments (Clarkson et al. 2010; Schallert, Hernandez, and Barth 1986) and retrospective human studies (Goldstein 1998, 1995) indicate activation at GABA receptors is detrimental to motor recovery. Though carefully matched placebo-controlled studies are the gold-standard for identifying the true effects of a given drug on motor recovery, these trials are costly and practically difficult. They must combine chronic drug administration with specific high-dose motor training (Kwakkel, Meskers, and Ward 2020).

Retrospective analysis that examines how drug prescriptions influence patients' response to rehabilitation programmes can provide a solution to some of these issues. In a naturalistic setting, prescriptions of common drugs come hand-in-hand with the co-morbidities they are aiming to treat, such as depression, epilepsy or spasticity. These issues may themselves impact on recovery, or interact with effects of the drug, making it difficult to draw conclusions about specific drug effects. However, using drug prescriptions to identify patients who systematically respond better or worse to a given intervention is the first step to singling out the causes of these disparities, and eventually leveraging these findings to improve interventions for all.

Another potential issue surrounding retrospective analysis of existing datasets is that, without pre-registration, researchers can be biased to make arbitrary analysis decisions motivated by results. A novel method, known as specification curve analysis (SCA), has been developed to tackle this problem (Simonsohn, Simmons, and Nelson 2019). Using SCA, all reasonable variations of a possible analytical test assessing each hypothesis are run. Rather than examining the results of individual tests, the results across all tests are therefore interpreted together to make a decision about whether to reject the null hypothesis (Simonsohn, Simmons, and Nelson 2019).

Aims

This retrospective study used SCA analysis to examine whether patients with prescriptions for certain classes of common drugs acting on the central nervous system (CNS) (i) differed in their level of impairment on admission to a high-dose Queen Square Upper-Limb (QSUL) rehabilitation programme and (ii) differed their response to the programme. The drug categories examined were GABA agonists, antiepileptics acting on sodium or calcium channels, and antidepressants.

Methods

Patient Data

Patients were referred to the QSUL programme by primary care physicians. The inclusion criteria for admission to the program was/is broad, focussing on whether patients were likely to achieve their goals for their upper-limb. There were no restrictions on time since stroke/injury or other demographic factors, but patients who experienced any of the following were not admitted: i) absent movement throughout the limb; (ii) a painful shoulder limiting an active forward reach (mostly due to adhesive capsulitis); (iii) severe spasticity or non-neural loss of range and (iv) unstable medical conditions. For more information regarding patient admission see Ward et al., 2019.

Between April 2014 and March 2020, a total of 439 first-time patients had been admitted to the 3-week programme. Of these, 321 patients had completed the 6 week and 6 month follow-up. There were several reasons that patients were not available for follow-up: some could not be contacted, considered it too far to travel, or suffered intercurrent illnesses; a large number were due for follow-up after the UK COVID-19 lockdown in March 2020. A further 15 patients were excluded as they did not have mood and/or fatigue measures recorded, and a final 29 patients were excluded as prescription drug information was not supplied at referral. This left a total of 277 patients for whom

full data sets were available. A break-down of demographics of the included 277 patients and the excluded 162 are provided in table 1.

	Included patients, n=277	Excluded patients, n=161	Statistical comparison
Age in years, mean (sd, range)	50.4 (15.2, 16-79)	53.0 (14.6, 16-84)	t(344)=-1.78, p=0.076
Gender, male	167	101	$\chi2(1)=0.164$, p=0.686
Time since incident in months, mean (sd, range)	36.8 (49.2, 2-340)	27.7 (38.9 2-409)	t(396)=2.12, **p=0.034**
Lesion type	H stroke = 76 I stroke = 172 Other/unknown = 29	H stroke = 41 I stroke = 90 Other/unknown = 30	$\chi2(2)=5.84$, p=0.054
Affected limb, right	140	86	$\chi2(1)=0.518$, p=0.472
Dominant Limb Affected	143	88	$\chi2(1)=0.261$, p=0.607
Admission BARTHEL, mean (sd)	18.1 (2.1)	17.9 (2.1)	t(315)=0.831, p=0.406
HADS score, mean (sd)	12.6 (6.6)	14.8 (8.5)	t(240)=-2.77**, p<0.001**
NFI score, mean (sd)	34.1 (10.7)	38.7 (11.1)	t(287)=-4.13, **p<0.001**

Table 1: Admission information for included and excluded patients

Upper-limb Measures

Function of the affected upper-limb was assessed on admission, discharge, 6 weeks and 6 months post-discharge using the following measures: Fugl-Meyer upper-limb (FM), Action Research Arm Test (ARAT), and the Chedoke Arm and Hand Activity Inventory (CAHAI). The FM is a stroke-specific, performance based impairment index. Here a modified version was used- excluding coordination and reflexes- which specifically focussed on motor synergies and joint function. This had a maximum score of 54 and the minimum clinically important difference (MCID) has been reported as 5.25 points (Page, Fulk, and Boyne 2012). The ARAT assesses patients' ability to handle objects of differing size, weight and shape. It has a maximum score of 57 and a MCID of 5.7 points (Van der Lee et al. 2001). Finally, the CAHAI focuses on how the arm and hand are incorporated into bilateral activities of daily living. The maximum score is 91 and though no MCID has been reported the minimum detectable change has been reported as 6.2 points (Barreca et al. 2005).

Additional Demographic or Subjective Measures

At admission two subjective measures, the Hospital Anxiety and Depression Scale (HADS) and the Neurological Fatigue Index (NFI), scored out of 42 and 69 respectively, were administered. Other

demographic information, e.g. age and sex, and neurological information, e.g. time since stroke/injury (at admission) and whether their dominant arm was affected, was also recorded.

Primary care physicians supplied each patient's prescribed drugs at the time of referral. Drugs acting on the CNS were grouped into three categories: GABA agonists, antiepileptics (acting on sodium or calcium channels), and antidepressants. Patients were coded as 'on' a category if they prescribed any one (or more) of the drugs within the category. Dose or prescription directions were not recorded. The specific drugs included in each category were: GABA agonists (n=49) – baclofen (n=41), clonazepam (n=3), diazepam (n=4), clobazam (n=2), and sodium valproate (n=3); antiepileptics (n=81) – topiramate (n=1), zonisamide (n=2), lamotrigine (n=13), lacosamide (n=4), (ox)carbazepine (n=2), phenytoin (n=3), levetiracetam (n=33), pregabalin (n=16) and gabapentin (n=21); antidepressants (n=56) - fluoxetine (n=9), citalopram (n=20), escitalopram (n=1), sertraline (n=10), paroxetine (n=2), duloxetine (n=2), venlafaxine (n=1), mirtazapine (n=9) and amitriptyline (n=9).

Analysis

All analyses were performed using R (RStudio version 1.1.456). Though this study had the clear objective of testing the effect of the CNS-acting drug prescriptions on motor recovery in the QSUL programme, as a retrospective analysis of existing data, pre-registration was not a convincing solution to eliminating bias in subjective analysis decisions. Increasingly, specification curve analyses (SCA) are being used to circumvent this problem for hypothesis testing on medium-to-large data sets (Simonsohn, Simmons, and Nelson 2019; Rohrer, Egloff, and Schmukle 2017; Orben, Dienlin, and Przybylski 2019; Orben and Przybylski 2019). SCA is a tool for mapping out an effect of interest across all potential, defensible, hypothesis tests examining an effect. Conclusions are drawn from the sum total of the results across all of the analyses rather than focussing on the results of only one test.

In this case, SCAs were run on a variety of linear models assessing the effect of each prescription drug group - GABA agonists, antiepileptics, and antidepressants - on (i) admission motor function and (ii) recovery/outcome at the 6 month timepoint. To assess the effect of the different prescriptions on admission scores, the regression coefficient (i.e. the magnitude of the effect of prescription on the admission score) and the p-value (i.e. whether this effect was statistically significant) were extracted from each of the linear models and fed into the SCA. The code is available here [provided on acceptance].

Identification of individual models for specification

For each of the three upper-limb measures- FM, ARAT and CAHAI- the score at admission was predicted from a linear regression model containing the prescription drug of interest and a variety of different covariates, grouped in pairs, which could be included or excluded from the analyses. These were: demographic information (i.e. age and sex); neurological incident information (i.e. time since incident and whether the dominant arm was primarily affected); subjective measures (i.e. HADS and NFI); and prescription of the other two drug groups. Inclusion or exclusion of outlying patients was also varied, where outlying patients were defined as having a recovery score ($T_{admission}$ to T_{6month}) that was outside 2.5*the interquartile range (IQR) from the median. This created a total of 96 different models, all assessing whether the prescription drug of interest influenced upper-limb function at admission. To allow easier comparison between the different upper-limb measures, each of which has a different scale, all measures were converted to a proportion of the maximum score (T_x/T_{Max}).

To assess the effect of each drug prescriptions on improvement, all three upper-limb measures were again examined, and the same set of covariates were either included or excluded. There are a variety of different ways improvement could be modelled: an outcome model, predicting the final T_{6month} score from the $T_{admission}$ score; an absolute recovery model, examining the change in score from $T_{admission}$ to T_{6month}; or a relative recovery model, predicting the amount of recovery achieved relative to the amount possible ((T_{6month} - $T_{admission}$)/(Max Score - $T_{admission}$)). This creates a total of 288 possible models all of which test the hypothesis that the drug prescription status influences motor improvement from the QSUL. Again, all outcome scores were proportions of the maximum possible score, and recovery scores were calculated using these proportions.

SCA models were also run to test the influence of HADS score on improvement. Models were the same as for testing for the effect of drug prescriptions, except all drugs were either included or excluded together, and NFI was included or excluded independent to HADS score.

Hypothesis testing of SCA

In each SCA, a certain proportion of the models examined will report an effect that reaches statistical significance ($p<0.05$). However, SCA aims to examine the evidence as a whole, summing across all the different individual models. In order to assess the statistical significance of the sum of evidence from a given SCA, a permutation method was used to generate the distribution of p-values, given the null hypothesis that the dependent variable (drug prescription) of interest has no effect on the independent variable (admission/improvement score) (Rohrer, Egloff, and Schmukle 2017). For each

199 SCA, in 500 permutations, the independent variables were shuffled, while keeping the dependent
200 variables and covariates un-shuffled. The total number of models with a significant effect of the
201 dependant variable, for each permutation of the SCA was then extracted. A p-value for each SCA was
202 calculated as the proportion of these permutations that had at least as many significant models as the
203 original data.

204 Results

205 Differences between included and excluded participants

206 To assess whether there were any differences in the demographics of participants who were included
207 in the analysis compared with those who were excluded, t-tests and chi-square tests were performed,
208 with full results reported in Table 1. Briefly, included participants tended to have greater time-since-
209 stroke ($t(396)=2.12$, $p=0.034$), lower HADS ($t(240)=-2.77$, $p<0.001$) and lower NFI ($t(287)=-4.13$,
210 $p<0.001$) scores, but were no different in any other measures. While these findings indicate that
211 included participants were less depressed/anxious and had less fatigue, the mean scores for both
212 groups on HADS indicate mild depression/anxiety symptoms (Stern 2014) and NFI scores were within
213 a normal range (Cumming et al. 2018).

214 GABA agonist prescriptions had a negative impact on admission scores, but
215 improvement was not affected.

216 SCA of the admission scores revealed that patients who had a prescription of GABA agonists were
217 significantly worse on admission to the QSUL ($p<0.002$). Of the 96 separate models run in the
218 admission SCA, 84 reported a significant effect of this drug category, and across all three of the
219 different admission measures GABA agonist prescription was found to negatively impact scores (see
220 Figure 3A). The mean value of the regression coefficients (β) for significant results was -0.085, with a
221 range of -0.115 to -0.066. This equates to a mean of 8.5% (range 6.6 – 11.5%) reduction in admission
222 scores in patients with a GABA agonist prescription relative to those without. Mean β across all
223 models was -0.083 (range -0.115 to -0.062).



Figure 1: The effect of GABA agonist prescription on measures of upper-limb function, across time.

Patients on GABA agonists had worse upper limb function at admission, but improved as expected during the programme. Dotted outline shows violin plot, solid lines show mean and standard error.

Using SCA to examine the effect of GABA agonist prescription on programme-related improvements in motor function did not generate sufficient evidence to reject the null hypothesis (p=0.266, 11/288 models significant, mean $\beta =$ -0.026, range -0.104 to 0.01; see Figure 2B).



Figure 2: SCA of the effect of GABA agonist prescription on measures of upper-limb function at admission (A) or improvement (B).

Each model, sorted by the size of the GABA agonist prescription regression coefficient, is represented by a line in the top panel. Red lines represent a significant effect of GABA agonist prescription on scores. Lines in the lower panels indicate the contents of the model. Patients on GABA agonists had worse upper limb function at admission, but improved as expected during the programme.

Antiepileptic prescriptions did not significantly affect either admission scores or programme-related improvements.

The results of the SCA revealed no overall significant effect of antiepileptic prescription on admission scores (p=0.152, 2/96 models significant, mean β = -0.039, range -0.066 to -0.022). (see Figure 4A). However, SCA of antiepileptic prescription on improvements revealed an effect approaching significance (p=0.052, 77/288 models significant, mean β = -0.032, range -0.159 to 0.006), driven by models examining ARAT scores.



Figure 3:The effect of antiepileptic prescription on measures of upper-limb function, across time.

Patients on and off antiepileptic drugs did not differ in admission or improvement scores. Dotted outline shows violin plot, solid lines show mean and standard error.



Figure 4: SCA of the effect of antiepileptic prescription on measures of upper-limb function at admission (A) or improvement (B)

Each model, sorted by the size of the antiepileptic prescription regression coefficient, is represented by a line in the top panel. Yellow lines represent a significant effect of antiepileptic prescription on scores. Lines in the lower panels indicate the contents of the model. Patients on and off antiepileptic drugs did not differ in admission or improvement scores.

Antidepressant prescriptions negatively impacted improvement on QSUL

There was no significant effect of antidepressant prescription on admission scores found using the SCA (p=0.094, 13/92 models significant, mean β = -0.058, range -0.076 to -0.041). However, the SCA found evidence of a negative effect of antidepressants on programme-related improvements (p=0.026, 143/288 models significant, mean β = -0.047, range -0.127 to -0.010). Significant effects were found across all measures, though predominantly in FM and ARAT. The magnitude of regression coefficients was higher using the recovery model, but a similar number of significant results were found across all model types. Covariate inclusion did not appear to reliably dictate model significance or regression coefficient size.



Figure 5: SCA of the effect of antidepressant prescription on measures of upper-limb function at admission (A) or improvement (B)

Each model, sorted by the size of the antidepressant prescription regression coefficient, is represented by a line in the top panel. Turquoise lines represent a significant effect of antidepressant prescription on scores. Lines in the lower panels indicate the contents of the model. Patients with antidepressant prescription did not differ in admission scores, but had lower programme-induced improvement scores.

Patients with antidepressant prescriptions had higher HADS scores than those without.

Although including subjective measures (i.e. HADS and NFI scores) in models predicting recovery did not systematically influence the significance or regression coefficient magnitude of the drug effect, we wanted to further examine the relationship between drug prescriptions and HADS score. Patients with antidepressant prescriptions had significantly higher depression/anxiety scores, as assessed by

two-sample t-test of HADS scores, than those without (t(88)=2.76, p=0.007) (see Figure 6A). This was not however the case for GABA agonist (t(66)=1.46, p=0.148) or antiepileptic prescriptions (t(136)=1.01, p=0.312). NFI score also did not differ by antidepressant prescription (t(91)=0.80, p=0.425).

To follow-up, a median split was performed on the HADS scores in patients without antidepressant prescription. These three groups (OnAD, OffAD-HighHADS, OffAD-LowHADS) had significantly different HADS scores (ANOVA: F(2,274)=142.3, p<0.001), and pairwise comparison showed that the AD+ group had significantly higher HADS score than the OffAD-LowHADS (Tukey HSD: diff=7.89, p<0.001) and significantly lower HADS than the OffAD-HighHADS group (Tukey HSD: diff=-2.44, p=0.004) (see Figure 6A). Visual inspection of the motor score data on the three measures, across the timepoints separated by these three groups again demonstrates the negative effect of antidepressant prescription on recovery even relative to the OffAD-HighHADS (see Figures 6B-D).



Figure 6: HADS score and upper-limb function scores split by antidepressant prescription

A, HADS scores for patients split by antidepressant prescription (black, turquoise), showing patients with antidepressant prescription have significant higher HADS score than those without. HADS scores for patients without antidepressant prescriptions, median split by HADS score, are also shown (light and dark grey). These groups have respectively higher and lower HADS scores than than the group on antidepressants. Dotted outlines are violin plots, solid dot/line shows mean and standard deviation.

B-C, upper-limb function scores across the measurement timepoints, split by antidepressant prescriptions and HADS scores. Visually demonstrating that patients with antidepressant prescriptions have poorer improvement than those without, even when comparing against only those with high HADS scores.

HADS score did not significantly influence admission scores or improvement

There was no significant effect of HADS on admission scores (p=0.170, 6/96 models significant, mean $\beta =$ -0.003, range -0.004 to -0.001) or improvement (p>0.999, 0/288 models significant, mean $\beta =$ -0.001, range -0.004 to 0.001).

Discussion

This retrospective study examined whether patients prescribed different classes of common, CNS-acting, drugs (GABA agonists, sodium or calcium channel blocking antiepileptics, or antidepressants) responded differently to an intensive, high-dose upper-limb rehabilitation programme. To test this robustly, SCA was used, where all sensible variations of models examining a certain hypothesis were run, and the sum of results across models was interpreted. Using this method patients prescribed GABA agonists were found to have worse upper-limb scores on admission to the programme but did not differ in terms of their improvement. This was in contrast to patients prescribed antidepressants, who did not differ on admission scores but had significantly poorer upper-limb improvement. There was no difference in admission or improvement scores in patients on antiepileptics.

Patients on GABA agonists had worse admission scores but improved just as well.

Across all three upper-limb measures, patients on GABA agonists had significantly worse admission scores, around a 6-10% reduction relative to those not prescribed the drug. Despite the large effect size, this difference is somewhat difficult to interpret. The drugs in the GABA agonist category are prescribed for diverse problems, for example baclofen (prescribed to 84% of the GABA agonist group) for spasticity or benzodiazepines (18% of GABA agonist group) for anxiety, insomnia and seizures. Clearly any differences in admission scores could be attributed either to the underlying co-morbidity for which the drug is prescribed, the effects of drug itself, or an association between the co-morbidity and increased stroke severity. While there were some control measures recorded at admission, e.g. HADS and NFI scores, there were not any measures of spasticity or sleep quality which might be relevant for assessing differences between those on and off GABA agonists.

Perhaps a more pertinent finding for clinical practice is the lack of significant difference in programme-related improvements in upper-limb function between patients on and off GABA agonists. Several studies have previously reported a correlational link between high GABA concentration (Blicher et al. 2014), or receptor activity (Kim et al. 2014; Bütefisch et al. 2008), and worse functional outcomes from rehabilitation post-stroke. Furthermore, a single dose of the $GABA_B$

317 agonist baclofen impairs aspects of motor learning in healthy humans (Johnstone et al., 2020); and
318 GABA antagonists can improve post-stroke motor recovery in rats (Clarkson et al. 2010; Schallert,
319 Hernandez, and Barth 1986). Given these findings, and another early retrospective study finding a
320 negative impact of benzodiazepine prescription on motor function recovery (Goldstein, 1995, though
321 see Nadeau et al., 2014), caution has previously been advised in the prescription of GABA agonists,
322 particularly benzodiazepines, post-stroke (Hesse and Werner 2003).

323 Yet in this data set, patients who were taking GABA agonists performed as expected, even despite co-
324 morbidities which could additionally hamper potential for improvement from the programme. The
325 result reported here should not, however, be taken as evidence that these drugs do not have
326 detrimental effects on motor rehabilitation- patients were often advised to take these medications at
327 night likely minimising their potential to interact with rehabilitation. Rather, this result should be
328 interpreted as the absence of negative effect of GABA agonists when they are prescribed
329 appropriately. It could also be argued that the symptoms which these drugs seek to treat, e.g.
330 spasticity or insomnia, may themselves worsen rehabilitative potential more than the drugs if left
331 unresolved (Fleming et al. 2020).

332 Sodium and calcium channel blocking antiepileptics did not impact admission scores 333 or motor improvements on the QSUL programme.

334 Stroke is the cause of 10% of all epilepsy cases (Feyissa, Hasan, and Meschia 2019) and so a great deal
335 of stroke patients, 29% in this data-set, are prescribed antiepileptics targeting sodium and calcium
336 channels. Here we found that there were no significant differences in admission motor scores in
337 patients prescribed antiepileptics versus those who were not. Comparing improvements on the QSUL
338 programme between the groups also resulted in a non-significant difference, however there was a
339 trend towards a decrease in improvements for patients on antiepileptics. Closer examination of this
340 finding shows that it was driven only by poorer improvements on one measure, the ARAT, with very
341 little effect on the CAHAI or FM, suggesting that this was not a robust effect across motor measures.

342 Though classic antiepileptic treatments, such as phenytoin or phenobarbital, have been suggested to
343 be detrimental to motor recovery in retrospective studies (Goldstein 1995), there is little evidence for
344 any influence of modern antiepileptic drugs on patient outcomes (Nadeau et al. 2014). In fact some
345 animal studies have even found neuroprotective benefits of Na channel blockers (Wang, Fessler, and
346 Chuang 2011). The results presented here align with a lack of significant effect of this class of drugs
347 on rehabilitation-induced motor improvements when prescribed appropriately.

Patients prescribed antidepressants do significantly worse on the QSUL programme.

Post-stroke depression is a frequent complication of stroke (Hackett and Pickles 2014; Ayerbe et al. 2013), most commonly treated by antidepressant prescription. Here we found that there were no significant differences in admission scores between patients with and without antidepressant prescriptions. However, when examining the programme-induced improvements in motor scores, patients on antidepressants did worse than those off the drugs. Significant effects were evenly distributed across different motor measures, whether examining outcome predicted by baseline or recovery, and whether subjective mood information (i.e. HADS and NFI scores) was included in the model or not.

A negative effect of antidepressants on motor improvements could be driven by effects of the drugs themselves, of the underlying depression, or a combination of the two. Patients with antidepressant prescription had higher HADS scores, i.e. had more symptoms of depression and anxiety, than those without. However, the persistence of the effect of antidepressant prescription while controlling for HADS, the non-significant effect of HADS on improvement, and the observation that patients on antidepressants do worse than patients with higher HADS scores but off antidepressants, indicates that there is some predictive power specific to this 'on antidepressants' category.

This result lies somewhat in contrast to the literature on the effect of SSRIs for post-stroke motor recovery. Inspired by the results of animal (Vetencourt et al. 2008) and smaller human studies (Dam et al. 1996; Pariente et al. 2001; Acler et al. 2009; Zittel, Weiller, and Liepert 2008), one medium sized placebo-controlled trial found that 3 months of 20mg fluoxetine daily, alongside physiotherapy, improved motor outcomes in chronic stroke patients (Chollet et al. 2011). More recent studies without additional universal concurrent physiotherapy have however, reported null results (Dennis et al. 2020; Lundström et al. 2020; Hankey et al. 2020), leading some to suggest that SSRIs are creating a brain environment conducive for plasticity which can then be exploited by concurrent rehabilitative training (Kwakkel, Meskers, and Ward 2020; Ng et al. 2015).

Here antidepressants (the vast majority of which were SSRIs, ~80%) were paired with rehabilitation, and so might be predicted to boost recovery. Some speculative reasons could be proposed for this divergence in findings: it may be that the beneficial effect of SSRIs does not persist in conjunction with depressive symptoms; or it could be that the antidepressant prescription is a better measure of trait depression, across the 6 month duration of the follow-up, than the one-time HADS score at admission, and the negative impact of these depressive symptoms may outweigh any positive impact of the drug. Further research is needed to identify a mechanistic explanation for this effect, but there

380 is still value in the observation that patients with antidepressant prescriptions tend to do worse on
381 intensive rehabilitation programmes. Identifying those patients who may respond less well to the
382 treatment is the first step in developing methods to improve interventions for these patients.

383 Conclusions

384 This retrospective study investigated the effects of prescriptions of three classes of commonly used,
385 CNS-acting, drugs on upper-limb improvements of 277 patients during the 3-week intensive QSUL
386 programme. Patients who were prescribed GABA agonist drugs tended to have worse upper-limb
387 scores at admission but responded equally well to the programme as those who were not. This
388 indicates that, when appropriately prescribed, GABA agonists do not impair upper-limb rehabilitation.
389 This was in contrast to patients with antidepressant prescriptions who did not have significantly
390 different upper-limb scores at admission, but who showed poorer improvement on the programme
391 that could not be explained by the HADS measure of depression and anxiety. If these patients can be
392 identified prior to admission, then differences in their needs on such programmes may be better
393 identified. There were no effects of antiepileptic drug prescriptions on either admission to, or
394 improvement on, the programme.

395 Acknowledgements

396 A Johnstone is funded by a project grant from the Dunhill Medical Trust. Thanks to all the
397 physiotherapists and occupational therapists at The National Hospital for Neurology and
398 Neurosurgery, Queen Square, who have treated patients on this programme. Thanks to UCLH
399 Charities, Friends of UCLH and The National Brain Appeal for funding to purchase equipment used in
400 this programme.

401

402

403 # Reference List

404 Acler, Michele, E Robol, A Fiaschi, and Paolo Manganotti. 2009. "A Double Blind Placebo RCT to
405 Investigate the Effects of Serotonergic Modulation on Brain Excitability and Motor Recovery in
406 Stroke Patients." *Journal of Neurology* 256 (7): 1152–58.

407 Allman, Claire, Ugwechi Amadi, Anderson M Winkler, Leigh Wilkins, Nicola Filippini, Udo Kischka,
408 Charlotte J Stagg, and Heidi Johansen-Berg. 2016. "Ipsilesional Anodal TDCS Enhances the
409 Functional Benefits of Rehabilitation in Patients after Stroke." *Science Translational Medicine* 8
410 (330): 330re1. https://doi.org/10.1126/scitranslmed.aad5651.

411 Association, Stroke. 2016. "Stroke Association, State of the Nation."
412 https://www.stroke.org.uk/sites/default/files/stroke_statistics_2015.pdf.

413 Ayerbe, Luis, Salma Ayis, Charles D A Wolfe, and Anthony G Rudd. 2013. "Natural History, Predictors
414 and Outcomes of Depression after Stroke: Systematic Review and Meta-Analysis." *British Journal*
415 *of Psychiatry* 202 (1): 14–21. https://doi.org/DOI: 10.1192/bjp.bp.111.107664.

416 Barreca, Susan R, Paul W Stratford, Cynthia L Lambert, Lisa M Masters, and David L Streiner. 2005.
417 "Test-Retest Reliability, Validity, and Sensitivity of the Chedoke Arm and Hand Activity Inventory:
418 A New Measure of Upper-Limb Function for Survivors of Stroke." *Archives of Physical Medicine*
419 *and Rehabilitation* 86 (8): 1616–22.

420 Blicher, Jakob Udby, Jamie Near, Erhard Næss-Schmidt, Charlotte J Stagg, Heidi Johansen-Berg, Jørgen
421 Feldbæk Nielsen, Leif Østergaard, and Yi-Ching Lynn Ho. 2014. "GABA Levels Are Decreased
422 After Stroke and GABA Changes During Rehabilitation Correlate With Motor Improvement."
423 *Neurorehabilitation and Neural Repair* 29 (3): 278–86.
424 https://doi.org/10.1177/1545968314543652.

425 Bütefisch, Cathrin M, Marion Weβling, Johannes Netz, Rüdiger J Seitz, and Volker Hömberg. 2008.
426 "Relationship between Interhemispheric Inhibition and Motor Cortex Excitability in Subacute
427 Stroke Patients." *Neurorehabilitation and Neural Repair* 22 (1): 4–21.

428 Chollet, François, Jean Tardy, Jean-François Albucher, Claire Thalamas, Emilie Berard, Catherine Lamy,
429 Yannick Bejot, et al. 2011. "Fluoxetine for Motor Recovery after Acute Ischaemic Stroke
430 (FLAME): A Randomised Placebo-Controlled Trial." *The Lancet Neurology* 10 (2): 123–30.
431 https://doi.org/10.1016/S1474-4422(10)70314-8.

432 Clarkson, Andrew N, Ben S Huang, Sarah E MacIsaac, Istvan Mody, and S Thomas Carmichael. 2010.
433 "Reducing Excessive GABA-Mediated Tonic Inhibition Promotes Functional Recovery after
434 Stroke." *Nature* 468 (7321): 305–9. https://doi.org/10.1038/nature09511.

435 Cumming, Toby B, Ai Beng Yeo, Jodie Marquez, Leonid Churilov, Jean-Marie Annoni, Umaru Badaru,
436 Nastaran Ghotbi, et al. 2018. "Investigating Post-Stroke Fatigue: An Individual Participant Data
437 Meta-Analysis." *Journal of Psychosomatic Research* 113: 107–12.
438 https://doi.org/https://doi.org/10.1016/j.jpsychores.2018.08.006.

439 Dam, M, P Tonin, A De Boni, Gilberto Pizzolato, S Casson, M Ermani, U Freo, L Piron, and L Battistin.
440 1996. "Effects of Fluoxetine and Maprotiline on Functional Recovery in Poststroke Hemiplegic
441 Patients Undergoing Rehabilitation Therapy." *Stroke* 27 (7): 1211–14.

442 Dennis, Martin, John Forbes, Catriona Graham, Maree Hackett, Graeme J Hankey, Allan House,

Stephanie Lewis, Erik Lundström, Peter Sandercock, and Gillian Mead. 2020. “Fluoxetine to Improve Functional Outcomes in Patients after Acute Stroke: The FOCUS RCT.” *Health Technology Assessment (Winchester, England)* 24 (22): 1–94. https://doi.org/10.3310/hta24220.

Feigin, Valery L, Mohammad H Forouzanfar, Rita Krishnamurthi, George A Mensah, Myles Connor, Derrick A Bennett, Andrew E Moran, Ralph L Sacco, Laurie Anderson, and Thomas Truelsen. 2014. “Global and Regional Burden of Stroke during 1990–2010: Findings from the Global Burden of Disease Study 2010.” *The Lancet* 383 (9913): 245–55.

Feyissa, A M, T F Hasan, and J F Meschia. 2019. “Stroke-Related Epilepsy.” *European Journal of Neurology* 26 (1): 18-e3. https://doi.org/10.1111/ene.13813.

Fleming, Melanie K, Tom Smejka, David Henderson Slater, Veerle van Gils, Emma Garratt, Ece Yilmaz Kara, and Heidi Johansen-Berg. 2020. “Sleep Disruption After Brain Injury Is Associated With Worse Motor Outcomes and Slower Functional Recovery.” *Neurorehabilitation and Neural Repair* 34 (7): 661–71. https://doi.org/10.1177/1545968320929669.

G. Broeks, J, G J Lankhorst, K Rumping, and A J H Prevo. 1999. “The Long-Term Outcome of Arm Function after Stroke: Results of a Follow-up Study.” *Disability and Rehabilitation* 21 (8): 357–64.

Goldstein, Larry B. 1995. “Common Drugs May Influence Motor Recovery after Stroke.” *Neurology* 45 (5): 865–71.

Goldstein, Larry B. 1998. “Potential Effects of Common Drugs on Stroke Recovery.” *Archives of Neurology* 55 (4): 454–56.

Hackett, Maree L, and Kristen Pickles. 2014. “Part I: Frequency of Depression after Stroke: An Updated Systematic Review and Meta-Analysis of Observational Studies.” *International Journal of Stroke* 9 (8): 1017–25. https://doi.org/10.1111/ijs.12357.

Hankey, Graeme J, Maree L Hackett, Osvaldo P Almeida, Leon Flicker, Gillian E Mead, Martin S Dennis, Christopher Etherton-Beer, Andrew H Ford, Laurent Billot, and Stephen Jan. 2020. “Safety and Efficacy of Fluoxetine on Functional Outcome after Acute Stroke (AFFINITY): A Randomised, Double-Blind, Placebo-Controlled Trial.” *The Lancet Neurology* 19 (8): 651–60.

Hesse, Stefan, and Cordula Werner. 2003. “Poststroke Motor Dysfunction and Spasticity.” *CNS Drugs* 17 (15): 1093–1107.

Johnstone, A., Grigoras, I., Petitet, P., Capitão, L., Stagg, C., J. 2020. "A single, clinically relevant dose of the GABAB agonist baclofen impairs visuomotor learning" *Journal of Physiology* (in press)

Kim, Yu Kyeong, Eun Joo Yang, Kyehee Cho, Jong Youb Lim, and Nam-Jong Paik. 2014. “Functional Recovery After Ischemic Stroke Is Associated With Reduced GABAergic Inhibition in the Cerebral Cortex: A GABA PET Study.” *Neurorehabilitation and Neural Repair* 28 (6): 576–83. https://doi.org/10.1177/1545968313520411.

Krakauer, John W, S Thomas Carmichael, Dale Corbett, and George F Wittenberg. 2012. “Getting Neurorehabilitation Right: What Can Be Learned from Animal Models?” *Neurorehabilitation and Neural Repair* 26 (8): 923–31.

Kwakkel, Gert, Carel G M Meskers, and Nick S Ward. 2020. “Time for the next Stage of Stroke Recovery Trials.” *The Lancet Neurology* 19 (8): 636–37. https://doi.org/10.1016/S1474-4422(20)30218-0.

Lee, Johanna H Van der, Vincent De Groot, Heleen Beckerman, Robert C Wagenaar, Gustaaf J Lankhorst, and Lex M Bouter. 2001. "The Intra-and Interrater Reliability of the Action Research Arm Test: A Practical Test of Upper Extremity Function in Patients with Stroke." *Archives of Physical Medicine and Rehabilitation* 82 (1): 14–19.

Lundström, Erik, Eva Isaksson, Per Näsman, Per Wester, Björn Mårtensson, Bo Norrving, Håkan Wallén, Jörgen Borg, Martin Dennis, and Gillian Mead. 2020. "Safety and Efficacy of Fluoxetine on Functional Recovery after Acute Stroke (EFFECTS): A Randomised, Double-Blind, Placebo-Controlled Trial." *The Lancet Neurology* 19 (8): 661–69.

Mawase, Firas, Kendra Cherry-Allen, Jing Xu, Manuel Anaya, Shintaro Uehara, and Pablo Celnik. 2020. "Pushing the Rehabilitation Boundaries: Hand Motor Impairment Can Be Reduced in Chronic Stroke." *Neurorehabilitation and Neural Repair* 34 (8): 733–45. https://doi.org/10.1177/1545968320939563.

Nadeau, Stephen E, Xiaomin Lu, Bruce Dobkin, Samuel S Wu, Yunfeng E Dai, Pamela W Duncan, and LEAPS Investigative Team. 2014. "A Prospective Test of the Late Effects of Potentially Antineuroplastic Drugs in a Stroke Rehabilitation Study." *International Journal of Stroke* 9 (4): 449–56.

Ng, Kwan L, Ellen M Gibson, Robert Hubbard, Juemin Yang, Brian Caffo, Richard J O'Brien, John W Krakauer, and Steven R Zeiler. 2015. "Fluoxetine Maintains a State of Heightened Responsiveness to Motor Training Early after Stroke in a Mouse Model." *Stroke* 46 (10): 2951–60.

Orben, Amy, Tobias Dienlin, and Andrew K Przybylski. 2019. "Social Media's Enduring Effect on Adolescent Life Satisfaction." *Proceedings of the National Academy of Sciences* 116 (21): 10226–28.

Orben, Amy, and Andrew K Przybylski. 2019. "The Association between Adolescent Well-Being and Digital Technology Use." *Nature Human Behaviour* 3 (2): 173–82.

Page, Stephen J, George D Fulk, and Pierce Boyne. 2012. "Clinically Important Differences for the Upper-Extremity Fugl-Meyer Scale in People with Minimal to Moderate Impairment Due to Chronic Stroke." *Physical Therapy* 92 (6): 791–98.

Pariente, Jérémie, Isabelle Loubinoux, Christophe Carel, Jean-François Albucher, Anne Leger, Claude Manelfe, Olivier Rascol, and François Chollet. 2001. "Fluoxetine Modulates Motor Performance and Cerebral Activation of Patients Recovering from Stroke." *Annals of Neurology* 50 (6): 718–29.

Rohrer, Julia M, Boris Egloff, and Stefan C Schmukle. 2017. "Probing Birth-Order Effects on Narrow Traits Using Specification-Curve Analysis." *Psychological Science* 28 (12): 1821–32.

Schallert, Timothy, T D Hernandez, and T M Barth. 1986. "Recovery of Function after Brain Damage: Severe and Chronic Disruption by Diazepam." *Brain Research* 379 (1): 104–11.

Simonsohn, Uri, Joseph P Simmons, and Leif D Nelson. 2019. "Specification Curve: Descriptive and Inferential Statistics on All Reasonable Specifications." *Available at SSRN 2694998*.

Stern, Anna F. 2014. "The Hospital Anxiety and Depression Scale." *Occupational Medicine* 64 (5): 393–94. https://doi.org/10.1093/occmed/kqu024.

Vetencourt, José Fernando Maya, Alessandro Sale, Alessandro Viegi, Laura Baroncelli, Roberto De Pasquale, Olivia F O'Leary, Eero Castrén, and Lamberto Maffei. 2008. "The Antidepressant Fluoxetine Restores Plasticity in the Adult Visual Cortex." *Science* 320 (5874): 385–88.

Wang, Zhi-fei, Emily Bame Fessler, and De-Maw Chuang. 2011. "Beneficial Effects of Mood Stabilizers Lithium, Valproate and Lamotrigine in Experimental Stroke Models." *Acta Pharmacologica Sinica* 32 (12): 1433–45. https://doi.org/10.1038/aps.2011.140.

Ward, Nick S, Fran Brander, and Kate Kelly. 2019. "Intensive Upper Limb Neurorehabilitation in Chronic Stroke: Outcomes from the Queen Square Programme." *Journal of Neurology, Neurosurgery &Amp; Psychiatry* 90 (5): 498 LP – 506. https://doi.org/10.1136/jnnp-2018-319954.

Zittel, Simone, Cornelius Weiller, and Joachim Liepert. 2008. "Citalopram Improves Dexterity in Chronic Stroke Patients." *Neurorehabilitation and Neural Repair* 22 (3): 311–14.